RÉSUMÉ
Arrhythmias and sudden cardiac death with sexual activity are rare. However, the demographics are changing regarding the cardiovascular patients at risk for these events. Recent studies have highlighted that the individuals having cardiac events during sexual activity are becoming younger, with a higher proportion of female decedents than previously described. There needs to be an open dialog between the cardiovascular team and the cardiac patient to provide the education and reassurance necessary for cardiovascular patients to participate in sexual intercourse safely. This paper reviews how sexual activity can lead to an increase in cardiac arrhythmias and sudden cardiac arrest in patients that are not medically optimized or are unaware of their underlying cardiac condition. The most common cardiovascular diseases associated with sexually induced arrhythmias and arrest are discussed regarding their potential risk and the psychosocial impact of this risk on these patients. Finally, cardiovascular medications and implantable cardioverter-defibrillators (ICDs) are addressed by reviewing the literature on the safety profile of these cardiac interventions in this patient population. Overall, sexual activity is safe for most cardiac patients, and providing proper education to the patient and their partner can improve the safety profile for patients with higher risk cardiovascular conditions. To give the appropriate education and reassurance necessary, cardiovascular team members need an understanding of the pathophysiology of how sexual activity can provoke arrhythmias and sudden cardiac arrest. Healthcare providers also need to build comfort in speaking to all patients and ensure that sexual partners, female patients, and those in the LGBTQIA + community receive the same access to counseling but tailored to their individual needs.
Sujet(s)
Fibrillation auriculaire/épidémiologie , Tolérance à l'effort , Exercice physique , Équivalent métabolique , Adulte , Facteurs âges , Alcoolisme/épidémiologie , Maladie des artères coronaires/épidémiologie , Entrainement d'endurance , Épreuve d'effort , Femelle , Valvulopathies/épidémiologie , Humains , Hypertension artérielle/épidémiologie , Hyperthyroïdie/épidémiologie , Mâle , Adulte d'âge moyen , Obésité/épidémiologie , Broncho-pneumopathie chronique obstructive/épidémiologie , Insuffisance rénale chronique/épidémiologie , Études rétrospectives , Facteurs de risque , Syndrome d'apnées obstructives du sommeil/épidémiologieRÉSUMÉ
COVID-19 poses a unique set of challenges to the healthcare system due to its rapid spread, intensive resource utilization, and relatively high morbidity and mortality. Healthcare workers are at especially high risk of exposure given the viruses spread through close contact. Reported cardiac complications of COVID-19 include myocarditis, acute coronary syndrome, cardiomyopathy, pericardial effusion, arrhythmia, and shock. Thus, echocardiography is integral in the timely diagnosis and clinical management of COVID-19 patients. Rush University Medical Center has been at the forefront of the COVID-19 response in Illinois with high numbers of cases reported in Chicago and surrounding areas. The echocardiography laboratory at Rush University Medical Center (RUMC) proactively took numerous steps to balance the imaging needs of a busy, nearly 700-bed academic medical center while maintaining safety.
Sujet(s)
COVID-19/complications , COVID-19/prévention et contrôle , Échocardiographie/méthodes , Cardiopathies/imagerie diagnostique , Cardiopathies/étiologie , Transmission de maladie infectieuse du patient au professionnel de santé/prévention et contrôle , Centres hospitaliers universitaires , Chicago , Humains , Équipement de protection individuelleRÉSUMÉ
PURPOSE: To determine the rates of sildenafil (Viagra) use among different populations, primarily among men who have sex with men, and to measure the association of sildenafil use with increased sexual risk behavior and sexually transmitted diseases (STDs), including human immunodeficiency virus (HIV) infection. METHODS: The National Center for Biotechnology Information PubMed was searched using a variety of terms for relevant publications from January 1999 to July 2004. In addition, all scientific abstracts from national and international conferences on STDs from January 1999 to July 2004 were searched. Relevant journal articles and scientific abstracts presenting original data and meeting given criteria were included. RESULTS: Fourteen studies met the inclusion criteria. Seven of the 11 studies in men who have sex with men showed sildenafil use rates >10% (range 3%-32%). Increased odds of unprotected anal sex with a partner of unknown or serodiscordant HIV status ranged from 2.0 to 5.7 times (mean = 3.9) for sildenafil users versus nonusers. The risk of sildenafil use and STD diagnosis among HIV-positive men who have sex with men was 1.92 (P = 0.05), and the odds of sildenafil use among those newly HIV infected was 2.5 (95% CI 1.1-4.1). CONCLUSIONS: Most studies reported frequent sildenafil use in men who have sex with men, and several showed independent associations between use of the drug and sexual risk behavior, as well as an increased risk for STDs, including incident HIV infection. Although future research among more varied participants is needed, these results warrant a multi-faceted response to reduce the misuse of sildenafil and its consequences, particularly among men who have sex with men.